Molecular targets for anti-oxidative protection of açaí berry against diabetes myocardial ischemia/reperfusion injury-Reference-Cited by-同舟云学术

Molecular targets for anti-oxidative protection of açaí berry against diabetes myocardial ischemia/reperfusion injury

Published:2023-05-04 Issue:5 Volume:57 Page:339-352
ISSN:1071-5762
Container-title:Free Radical Research
language:en
Short-container-title:Free Radical Research

Author:

Impellizzeri Daniela¹,Cordaro Marika²,Siracusa Rosalba¹,Fusco Roberta¹,Peritore Alessio Filippo³,Gugliandolo Enrico³,Genovese Tiziana¹,Crupi Rosalia³,Interdonato Livia¹,Evangelista Maurizio⁴,Di Paola Rosanna³,Cuzzocrea Salvatore¹,D’Amico Ramona¹

Affiliation:

1. Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy

2. Department of Biomedical, Dental and Morphological and Functional Imaging, University of Messina, Messina, Italy

3. Department of Veterinary Science, University of Messina, Messina, Italy

4. Institute of Anaesthesiology and Reanimation, Catholic University of the Sacred Heart, Rome, Italy

Publisher

Informa UK Limited

Subject

General Medicine,Biochemistry

Link

https://www.tandfonline.com/doi/pdf/10.1080/10715762.2023.2243032

Reference86 articles.

1. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

2. The Antioxidant Activity of Pistachios Reduces Cardiac Tissue Injury of Acute Ischemia/Reperfusion (I/R) in Diabetic Streptozotocin (STZ)-Induced Hyperglycaemic Rats

3. Systematic Review of the Epidemiology and Natural History of the Metabolic Vascular Syndrome and its Coincidence with Type 2 Diabetes Mellitus and Cardiovascular Diseases in Different European Countries

4. Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases

5. Anticoagulation Control in Warfarin -Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin – Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial)